Oxford Biomedica (OXB) Trading Update summary

Acquisition details

• Acquired the remaining 10% stake in its US subsidiary from Q32 Bio, achieving full ownership as planned.

• The US subsidiary, established in Bedford, MA in 2022, focuses on AAV manufacturing and innovation.

• The facility has integrated OXB's lentiviral platform and supports multiple new US programs.

• Full ownership aligns with the global strategy and supports long-term growth in viral vector manufacturing.

• The US site spans 96,000 ft² and offers both lentiviral and AAV vector capabilities.

Strategic impact and capabilities

• Strengthens position in the US market and meets growing demand for high-quality vector manufacturing.

• Enables support for clients globally across all key vector types, from early-stage development to commercialisation.

• OXB's network includes sites in the UK, France, and the US, providing deep expertise in AAV and lentiviral therapies.

• Offers unique technologies such as the TetraVecta system and dual-plasmid AAV production.

• Supported by robust quality assurance, analytical methods, and regulatory expertise.